Logo - springer
Slogan - springer

Birkhäuser - Birkhäuser BioSciences | Advances in Targeted Cancer Therapy

Advances in Targeted Cancer Therapy

Series: Progress in Drug Research, Vol. 63

Schultz, Richard M. (Ed.)

2005, VII, 303 p.

A product of Birkhäuser Basel
Available Formats:
eBook
Information

Springer eBooks may be purchased by end-customers only and are sold without copy protection (DRM free). Instead, all eBooks include personalized watermarks. This means you can read the Springer eBooks across numerous devices such as Laptops, eReaders, and tablets.

You can pay for Springer eBooks with Visa, Mastercard, American Express or Paypal.

After the purchase you can directly download the eBook file or read it online in our Springer eBook Reader. Furthermore your eBook will be stored in your MySpringer account. So you can always re-download your eBooks.

 
$249.00

(net) price for USA

ISBN 978-3-7643-7414-3

digitally watermarked, no DRM

Included Format: PDF

download immediately after purchase


learn more about Springer eBooks

add to marked items

Hardcover
Information

Hardcover version

You can pay for Springer Books with Visa, Mastercard, American Express or Paypal.

Standard shipping is free of charge for individual customers.

 
$319.00

(net) price for USA

ISBN 978-3-7643-7174-6

free shipping for individuals worldwide

usually dispatched within 3 to 5 business days


add to marked items

There have been tremendous advances in our understanding of molecular and tumor biology during the past few years. In the field of cancer therapeutics, it is expected that cytotoxic drug approaches will be gradually replaced with treatments based on biological targeted approaches. Hopefully these new targeted therapies will significantly increase efficacy and lack the devastating and troublesome side effects elicited by cytotoxic chemotherapy.

This volume is the first book to cover the general topic of targeted cancer therapy. It presents a range of targets such as tumor angiogenesis, cell cycle control and cell signalling, COX-2, apoptosis/cell survival, invasion and metastasis and approaches like kinase inhibitors, antisense, and antibody-based therapeutics. The emphasis is on preclinical development, including target validation, development of biomarkers, strategies for combination approaches, and development of resistance. The particular challenges involved in translating these data to clinical application are discussed.
This volume should be of broad general interest to researchers and clinicians involved in cancer therapy as well as other scientists interested in current strategies for cancer treatment.

Content Level » Professional/practitioner

Keywords » angiogenesis - antibody - apoptosis - cancer - cancer prevention - cancer therapy - cancer treatment - cell - metastasis - pharmacology - prevention - receptor - tumor

Related subjects » Birkhäuser BioSciences

Table of contents 

Dawn of a new era in molecular cancer therapeutics.- Obtacles and opportunities in the clinical development of targeted therapeutics.- Tumor models for preclinical development of targeted agents.- Angiogenesis inhibitors: What is the clinical future?.- Epidermal growth factor receptor (EGFR) inhibitors in cancer therapy.- Cell survival signaling during apoptosis: Implications in drug resistance and anti-cancer therapeutic development.- Targeted histone deacetylase inhibition for cancer prevention and therapy.- Inhibitors of cyclin-dependent kinase modulators for cancer therapy.- Targeting cyclooxygenase-2 for cancer prevention and treatment.- Antisense approaches in drug discovery and development.- Preclinical development of Alimta™ (Pemetrexed, LY231514), a multitargeted antifolate.

Popular Content within this publication 

 

Articles

Read this Book on Springerlink

Services for this book

New Book Alert

Get alerted on new Springer publications in the subject area of Cancer Research.